Corcept Therapeutics (CORT) Stock Price, News & Analysis

Company Overview

Corcept Therapeutics Incorporated is a biopharmaceutical company focused on discovering and developing medicines that modulate the effects of the stress hormone cortisol. The company’s research centers on the glucocorticoid receptor, which regulates cortisol activity and may play a role in metabolic, psychiatric, oncologic and other serious diseases.

Corcept’s commercial product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery. The company supports the product through commercial and medical services for healthcare providers and patients.

The company is also developing relacorilant, a selective glucocorticoid receptor modulator, for potential use in Cushing’s syndrome and other conditions in which excess cortisol activity may contribute to disease. Corcept was founded in 1998 and is headquartered in Menlo Park, California. Its commercial operations are centered in the United States, while its clinical development programs may involve research sites and participants in multiple regions. Joseph K. Belanoff, M.D., a co-founder of the company, serves as chief executive officer.

Key Stats

• Today's Range: $114.51 to $120.44
• 50-Day Range: $90.88 to $123.57
• 52-Week Range: $28.66 to $126.38
• Volume: 794,942 shs
• Average Volume: 1.69 million shs
• Market Capitalization: $12.55 billion
• P/E Ratio: 276.44
• Dividend Yield: N/A
• Price Target: $138.17
• Consensus Rating: Moderate Buy

Corcept Therapeutics Stock Analysis - MarketRank™

Corcept Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 249th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Corcept Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 5 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Corcept Therapeutics has a consensus price target of $138.17, representing about 19.0% upside from its current price of $116.10.

Amount of Analyst Coverage

Corcept Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 87.10%

Earnings Growth

Earnings for Corcept Therapeutics are expected to grow by 87.10% in the coming year, from $1.86 to $3.48 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Corcept Therapeutics is 276.44, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.92.

Price to Earnings Ratio vs. Sector

The P/E ratio of Corcept Therapeutics is 276.44, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 276.12.

Price to Book Value per Share Ratio

Corcept Therapeutics has a P/B Ratio of 18.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.91% of the float of Corcept Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Corcept Therapeutics has a short interest ratio ("days to cover") of 9.91.

Change versus previous month

Short interest in Corcept Therapeutics has recently decreased by 0.51%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Corcept Therapeutics does not currently pay a dividend.

Dividend Growth

Corcept Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: 0.46

News Sentiment

Corcept Therapeutics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Corcept Therapeutics this week, compared to 12 articles on an average week.

Search Interest

Only 5 people have searched for CORT on MarketBeat in the last 30 days. This is a decrease of -72% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Corcept Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Corcept Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $50,674,595.00 in company stock.

Percentage Held by Insiders

20.70% of the stock of Corcept Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

93.61% of the stock of Corcept Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/29/2026
• Today: 9/26/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CORT
• CIK: 1088856
• Web: www.corcept.com
• Phone: (650) 327-3270
• Fax: 650-327-3218
• Employees: 730
• Year Founded: 1998

Price Target and Rating

• Average Price Target for Corcept Therapeutics: $138.17
• High Price Target: $165.00
• Low Price Target: $50.00
• Potential Upside/Downside: +19.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.42
• Trailing P/E Ratio: 276.44
• Forward P/E Ratio: 62.42
• P/E Growth: N/A
• Net Income: $99.65 million
• Net Margins: 6.52%
• Pretax Margin: 3.17%
• Return on Equity: 8.26%
• Return on Assets: 6.45%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.86
• Quick Ratio: 2.77

Sales & Book Value

• Annual Sales: $761.41 million
• Price / Sales: 16.48
• Cash Flow: $0.88 per share
• Price / Cash Flow: 131.28
• Book Value: $6.16 per share
• Price / Book: 18.85

Miscellaneous

• Outstanding Shares: 108,100,000
• Free Float: 85,722,000
• Market Cap: $12.55 billion
• Optionable: Optionable
• Beta: 0.45